DOJ & Patent Office To Host Workshop On Innovation In The Life Science Sector

The Justice Department’s Antitrust Division (DOJ) and the U.S. Patent and Trademark Office (USPTO) will host a virtual public workshop on Sept. 23rd and 24th, 2020 to discuss the importance of intellectual property rights and pro-competitive collaborations for life sciences companies, research institutions, and American consumers.
“Now more than ever, it is essential that we consider the role of regulation and antitrust enforcement on incentives for innovation in key areas of discovery, such as biotechnology and the life sciences,” said Assistant Attorney General for the Antitrust Division Makan Delrahim. “We look forward to a robust discussion of the current legal climate and its impact on competitiveness, and are honored to collaborate with Director Iancu and his talented team at the PTO in hosting this event.”
The workshop will feature a fireside chat between Assistant Attorney General Delrahim and Under Secretary of Commerce for Intellectual Property and Director of the USPTO, Andrei Iancu. Former Director of the National Institutes of Health, Dr. Elias A. Zerhouni will deliver a keynote address. The workshop will include panel discussions of how patents and copyrights incentivize and reward innovation in the life science sector and the USPTO’s guidance on patentability for life sciences inventions. In addition, panels will discuss how partnerships and collaboration can facilitate the development of complex biologics, and the role of antitrust enforcement and regulation in preserving competition and incentives for innovation among drug developers and their partners. Panelists include leading figures from industry, government agencies, prominent research labs, the non-profit sector, academia, and the broader legal and economic community.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas